VANCOUVER, BC, and NATICK, MA, Nov. 8 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) and its corporate partner, Boston Scientific Corporation (NYSE:BSX) announced today that they have jointly received the Canadian American Business Council (CABC) 2005 Achievement Award, which recognizes innovative and successful alliances between Canadian and American firms. The award was presented today at the Council's 11th annual business achievement awards ceremony and policy forum held in Calgary, Alberta, Canada. The CABC Achievement Award is given each year to two companies whose cross-border joint enterprise has demonstrated strong business growth, remarkable innovation, and the capacity to provide the allies with a global advantage. The winners are chosen by an international panel of judges using standards that examine sustained profitability, job creation, financial strength, environmental responsibility, corporate synergy, exceptional imagination and remarkable innovation. "We are very pleased that our alliance with Angiotech has been recognized by the CABC," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "The innovative combination of our TAXUS(R) stent technology with Angiotech's paclitaxel drug technology has resulted in the world's most successful drug-eluting coronary stent system. The 1.8 million stents implanted to date in patients worldwide is a testament to the strength of the alliance, and to the employees at Boston Scientific and Angiotech who made this revolutionary technology possible." "This award is a tribute to the hard work and dedication of employees at both companies," said William Hunter, Chief Executive Officer of Angiotech. "The complexity of the joint project was enormous but we were able to marry our separate pharmaceutical and device technologies to deliver an innovative combination product for the global market." Executives from Boston Scientific and Angiotech also participated in a policy forum and panel discussion titled "The Cross Border Security and Prosperity Partnership". BSC acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co-exclusive rights to other vascular and non-vascular products. About The Canadian American Business Council The Canadian American Business Council is the premier voice of the Canadian-American business community and is headquartered in Washington, D.C. Established in 1987, the Council is a non-profit, issues-oriented organization dedicated to elevating the private sector perspective on issues that affect Canada and the United States. For more information, please visit http://www.canambusco.org/. About Angiotech Pharmaceuticals Vancouver-based Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, is dedicated to enhancing the performance of medical devices and biomaterials through the innovative uses of pharma-therapeutics. To find out more about Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), please visit our website at http://www.angiotech.com/. About Boston Scientific Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/. Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements. CONTACT: Boston Scientific Angiotech Pharmaceuticals ----------------- ------------------------- Milan Kofol Todd Young 508-650-8569 604-221-7676 ext 6933 Investor Relations VP Investor Relations & Boston Scientific Communications Corporation Angiotech Pharmaceuticals, Inc. Paul Donovan Rui Avelar 508-650-8541 604-221-7676 ext 6996 Media Relations Sr. VP Medical Affairs & Boston Scientific Communications Corporation Angiotech Pharmaceuticals, Inc. Colleen Beauregard 503-443-7863 Media Relations Waggener Edstrom Bioscience DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Boston Scientific, Milan Kofol, (508) 650-8569, Investor Relations, Boston Scientific Corporation; Paul Donovan, (508) 650-8541, Media Relations, Boston Scientific Corporation; Angiotech Pharmaceuticals, Todd Young, (604) 221-7676 ext 6933, VP Investor Relations & Communications, Angiotech Pharmaceuticals, Inc.; Rui Avelar, (604) 221-7676 ext 6996, Sr. VP Medical Affairs & Communications, Angiotech Pharmaceuticals, Inc.; Colleen Beauregard, (503) 443-7863, Media Relations, Waggener Edstrom Bioscience

Copyright